Table 1 Characteristics of studies included in the present meta-analysis
Study ID | Study design | RCT no. | Population (corticosteroids/control) | Type of influenza | Type of corticosteroids | Initial dose of corticosteroids (mean ± SD) | Antiviral drug |
|---|---|---|---|---|---|---|---|
Brun-Buisson [13] | Retrospective analysis | NR | 83/125 | H1N1 | 57.8% hydrocortisone 37.3% methylprednisolone 4.8% prednisone | 328 ± 160 (equivalent hydrocortisone) | NR |
Cao [15] | Retrospective study | NR | 204/84 | H7N9 | 91.7% methylprednisolone 3.9% dexamethasone 2.5% hydrocortisone 2.0% others | 81.1 ± 83.2 (equivalent methylprednisolone) | Corticosteroids group: 201/204 Control group: 84/84 |
Diaz [12] | Prospective observational multicenter study | NR | 136/236 | H1N1 | NR | NR | Corticosteroids group: 136/136 Control group: 236/236 |
Jung [16] | Multicenter retrospective study | NR | 99/120 | H1N1 | NR | NR | Survivor: 130/141 Death: 68/78 |
Perez-Padilla [17] | Retrospective study | NR | 7/11 | H1N1 | NR | NR | NR |
Lee [18] | Cohort study | NR | 264/817 | H1N1 | NR | NR | 151 in all the patients |
Li [19] | Case control | NR | 1055/1086 | H1N1 | 89.0% methylprednisolone 8.1% dexamethasone 2.0% hydrocortisone 0.9% prednisolone | 141.3 ± 142 (equivalent methylprednisolone) | Corticosteroids: 1025/1055 Control group: 1022/1086 |
Moreno [20] | Secondary analysis of a prospective cohort study | NR | 604/1242 | Viral A/B/C | 95.7% methylprednisolone; 3.8% prednisolone; 0.5% dexamethasone | A median (interquartile range) daily dose equivalent to 80 (60–120) mg of methylprednisolone | NR |
Rois [21] | Multicenter prospective study | NR | 75/103 | H1N1 | NR | NR | Survivors: 91/93 Death: 82/85 |
Viasus [22] | Observational, prospective cohort study | NR | 37/160 | H1N1 | NR | NR | Corticosteroids group: 8/37 Control group: 41/160 |